Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07013435 · ClinicalTrials.gov registry record · NA
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
A NA study, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- NA
- Development phase
- 254
- Enrollment target
NCT07013435: Clinical Trial NA study, sponsored by Massachusetts General Hospital.
NCT07013435 is a NA study that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 254 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07013435, a NA study, has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 254 participants
- Enrollment target
Study Summary
The goal of this trial is to learn if a resilience intervention can lead to improvements in lymphoma survivors' quality of life.
Primary Outcome
To examine the effects of the SMART3RP-Lymphoma vs. a Health Education Program (HEP) in improving quality of life in early posttreatment lymphoma survivors. Quality of life will be measured using the PROMIS-29 which assesses physical, functional, emotional, and social quality of life. Each survey item is measured on a 1-5 scale. The unit of measurement is a score on a scale.
Interventions
- OTHER Health Education Program
- OTHER SMART3RP-Lymphoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2026-07-20 |
| Est. Completion | 2030-08 |
| Phase | NA |
What is known before NCT07013435 opens enrollment
NCT07013435 is an interventional study that assigns participants to a tested intervention. The registered 254 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 2 interventions - of which Health Education Program is the first listed.
NCT07013435 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07013435 about?
NCT07013435 is a clinical study titled "A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship". The goal of this trial is to learn if a resilience intervention can lead to improvements in lymphoma survivors' quality of life.
What is the current status of trial NCT07013435?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 254 participants. The study started on 2026-07-20. Estimated completion is 2030-08.
What interventions are being tested in trial NCT07013435?
The interventions under investigation include: Health Education Program (OTHER), SMART3RP-Lymphoma (OTHER).
Who is sponsoring clinical trial NCT07013435?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07013435's enrollment target sits among peer trials
254 407th of 2000 higher than 1,594 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04390737 · 254 participants · Phase 1
Evaluate the Safety and Clinical Activity of HH2853
- NCT04677647 · 254 participants · NA
OurChild: A Health IT Solution to Reduce Minority Health Disparities
- NCT05503797 · 254 participants · Phase 2
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- NCT06167317 · 254 participants · Phase 1
Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI